The Blind Spot in Cancer Immunotherapy: Statistical Profile And Epidemiology of Immune-Related Organ Toxicities of Checkpoint Inhibitors

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., et al. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer, 9(6), e002435. doi:10.1136/jitc-2021-002435.

Schneider, B. J., Naidoo, J., Santomasso, B. D., et al. (2021). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. Journal of Clinical Oncology, 39(36), 4073-4126. doi:10.1200/JCO.21.01440.

Haanen, J., Obeid, M., Spain, L., et al. (2022). Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 33(12), 1217-1238. doi:10.1016/j.annonc.2022.10.001.

National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. U.S. Department of Health and Human Services, National Institutes of Health.

Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019). Adverse events following cancer immunotherapy: Obstacles and opportunities. Trends in Immunology, 40(6), 511-523. doi:10.1016/j.it.2019.04.002.

Arnaud-Coffin, P., Maillet, D., Gan, H. K., Stelmes, J. J., You, B., Dalle, S., & Péron, J. (2019). A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. International Journal of Cancer, 145(3), 639-648. doi:10.1002/ijc.32132.

Xu, C., Chen, Y. P., Du, X. J., et al. (2018). Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis. BMJ, 363, k4226. doi:10.1136/bmj.k4226.

Patrinely, J. R. Jr., Johnson, R., Lawless, A. R., et al. (2021). Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncology, 7(5), 744-748. doi:10.1001/jamaoncol.2021.0051.

Nielsen, D. L., Juhl, C. B., Nielsen, O. H., Chen, I. M., & Herrmann, J. (2024). Immune checkpoint inhibitor-induced cardiotoxicity: A systematic review and meta-analysis. JAMA Oncology, 10(10), 1390-1399. doi:10.1001/jamaoncol.2024.3065.

Mahmood, S. S., Fradley, M. G., Cohen, J. V., et al. (2018). Myocarditis in patients treated with immune checkpoint inhibitors. Journal of the American College of Cardiology, 71(16), 1755-1764. doi:10.1016/j.jacc.2018.02.037.

Johnson, D. B., Balko, J. M., Compton, M. L., et al. (2016). Fulminant myocarditis with combination immune checkpoint blockade. New England Journal of Medicine, 375(18), 1749-1755. doi:10.1056/NEJMoa1609214.

Wang, D. Y., Salem, J. E., Cohen, J. V., et al. (2018). Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncology, 4(12), 1721-1728. doi:10.1001/jamaoncol.2018.3923.

Dougan, M., Wang, Y., Rubio-Tapia, A., & Lim, J. K. (2021). AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review. Gastroenterology, 160(4), 1384-1393. doi:10.1053/j.gastro.2020.08.063.

Cortazar, F. B., Kibbelaar, Z. A., Glezerman, I. G., et al. (2020). Clinical features and outcomes of immune checkpoint inhibitor-associated acute kidney injury: A multicenter study. Journal of the American Society of Nephrology, 31(2), 435-446. doi:10.1681/ASN.2019070676.

Naidoo, J., Wang, X., Woo, K. M., et al. (2017). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology, 35(7), 709-717. doi:10.1200/JCO.2016.68.2005.

Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., et al. (2018). Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncology, 4(2), 173-182. doi:10.1001/jamaoncol.2017.3064.

Gao, R., Liang, W., Chen, J., Yang, M., Yu, X., & Wang, X. (2025). Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A real-world disproportionality analysis based on the FDA Adverse Event Reporting System. BMC Cancer, 25(1), 216. doi:10.1186/s12885-025-13614-1.

Tong, L., Yuan, Y., He, W., Yang, W., & Pan, X. (2025). Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Expert Opinion on Drug Safety, 1-9. doi:10.1080/14740338.2025.2486311.

Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety, 18(6), 427-436. doi:10.1002/pds.1742.

Evans, S. J. W., Waller, P. C., & Davis, S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety, 10(6), 483-486. doi:10.1002/pds.677.

DuMouchel, W. (1999). Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. The American Statistician, 53(3), 177-190. doi:10.1080/00031305.1999.10474456.

Reynolds, K. L., Arora, S., Elayavilli, R. K., et al. (2021). Immune-related adverse events associated with immune checkpoint inhibitors: A call to action for collecting and sharing clinical trial and real-world data. Journal for ImmunoTherapy of Cancer, 9(7), e002896. doi:10.1136/jitc-2021-002896.

Hazell, L., & Shakir, S. A. W. (2006). Under-reporting of adverse drug reactions: A systematic review. Drug Safety, 29(5), 385-396. doi:10.2165/00002018-200629050-00003.

Pariente, A., Gregoire, F., Fourrier-Reglat, A., Haramburu, F., & Moore, N. (2007). Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias. Drug Safety, 30(10), 891-898. doi:10.2165/00002018-200730100-00007.

Pearson, R. K., Hauben, M., Goldsmith, D. I., et al. (2009). Influence of the MedDRA hierarchy on pharmacovigilance data mining results. International Journal of Medical Informatics, 78(12), e97-e103. doi:10.1016/j.ijmedinf.2009.01.001.

Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J., & Manne, A. (2022). Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Frontiers in Immunology, 13, 779691. doi:10.3389/fimmu.2022.779691.

Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern epidemiology (3rd ed.). Lippincott Williams & Wilkins.

Sweeting, M. J., Sutton, A. J., & Lambert, P. C. (2004). What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine, 23(9), 1351-1375. doi:10.1002/sim.1761.

Austin, P. C., Lee, D. S., & Fine, J. P. (2016). Introduction to the analysis of survival data in the presence of competing risks. Circulation, 133(6), 601-609. doi:10.1161/CIRCULATIONAHA.115.017719.

Higgins, J. P. T., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21(11), 1539-1558. doi:10.1002/sim.1186.

Stijnen, T., Hamza, T. H., & Özdemir, P. (2010). Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Statistics in Medicine, 29(29), 3046-3067. doi:10.1002/sim.4040.

Barendregt, J. J., Doi, S. A., Lee, Y. Y., Norman, R. E., & Vos, T. (2013). Meta-analysis of prevalence. Journal of Epidemiology and Community Health, 67(11), 974-978. doi:10.1136/jech-2013-203104.

Sun, X., Briel, M., Walter, S. D., & Guyatt, G. H. (2010). Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ, 340, c117. doi:10.1136/bmj.c117.

Sauzet, O., Carvajal, A., Escudero, A., Molokhia, M., & Cornelius, V. R. (2013). Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data. Drug Safety, 36(10), 995-1006. doi:10.1007/s40264-013-0061-7.

Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022). Immune-checkpoint inhibitors: Long-term implications of toxicity. Nature Reviews Clinical Oncology, 19(4), 254-267. doi:10.1038/s41571-022-00600-w.

Collins, G. S., Moons, K. G. M., Dhiman, P., et al. (2024). TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ, 385, e078378. doi:10.1136/bmj-2023-078378.

Van Calster, B., McLernon, D. J., van Smeden, M., Wynants, L., & Steyerberg, E. W. (2019). Calibration: The Achilles heel of predictive analytics. BMC Medicine, 17(1), 230. doi:10.1186/s12916-019-1466-7.

Hartnell, N. R., & Wilson, J. P. (2004). Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy, 24(6), 743-749. doi:10.1592/phco.24.8.743.36068.

Gupta, S., Belouali, A., Shah, N. J., Atkins, M. B., & Madhavan, S. (2021). Automated identification of patients with immune-related adverse events from clinical notes using word embedding and machine learning. JCO Clinical Cancer Informatics, 5, 541-549. doi:10.1200/CCI.20.00109.

Lundberg, S. M., & Lee, S.-I. (2017). A unified approach to interpreting model predictions. In Advances in Neural Information Processing Systems 30 (pp. 4765-4774). Curran Associates.